New strategy to combat cancer: streamlining blood vessel walls

VIB News 6/02/2009

Leuven – Our blood vessels have a built-in rescue-mechanism that springs into action when there is insufficient oxygen in our tissues. VIB scientists at the Katholieke Universiteit Leuven have now discovered that this mechanism can be mobilized in the battle against cancer. When there is a shortage of oxygen, the cells lining the inner wall of blood vessels acquire a different shape, and they behave differently, too. The researchers have named this new appearance a “phalanx cell”. This newly discovered mechanism offers new possibilities for the treatment of cancer as well as of other disorders that are accompanied by a shortage in oxygen, such as certain heart diseases and age-related blindness.

Our blood vessels provide all growing tissues with oxygen and nutrients. The growth of blood vessels (a process termed angiogenesis) is indispensable for the proper functioning of organs and the repair of tissues when they have become damaged.

“Phalanx” cell

Many studies have been performed on how blood vessels form, but still little is known about the molecular mechanisms that determine the shape and the behavior of the lining of a blood vessel, the so-called endothelial cells. Massimiliano Mazzone and his colleagues, under the direction of Peter Carmeliet, have been studying in endothelial cells the role of a protein, PHD2, that serves as an oxygen sensor.

The researchers have been able to show that a reduced activity of the oxygen sensor PHD2 in case of oxygen shortage leads to the formation of a close-fitting, smooth, cobblestone-shaped lining of endothelial cells. This contiguous row of cells resembles a phalanx, the tightly-knit formation of soldiers with shields touching each other that the Greeks in classical antiquity used to win historical victories. This phalanx streamlines blood vessels, which improves the supply of oxygen – and medicines – to the surrounding tissue.

New treatments?

This discovery is an important breakthrough for the treatment of cancer. The larger a tumor grows, the more oxygen it requires. The tumor tries to remedy this situation by producing growth factors that stimulate the growth of new blood vessels. However, these new blood vessels have an abnormal shape, which impairs blood flow so that the cancer cells receive little oxygen. This shortage of oxygen forces cancer cells to escape the tumor and to metastasize to distant organs, which ultimately results in a malignant cancer. In addition, the abnormal shape of the blood vessels restricts the delivery and effectiveness of anti-cancer medicines.
PHD2-blockers can offer new possibilities to combat cancer. By converting the abnormal endothelial layer into a phalanx of tightly aligned and impermeable cells, anti-cancer medicines can reach their destination more easily, and chemotherapy is improved. Furthermore, through the improved oxygen supply, the cancer cells are much less inclined to travel elsewhere. In addition, such a phalanx barrier of endothelial cells physically prevents cancer cells from worming their way to the blood inside the vessel and, thus, these cancer cells no longer have a chance to travel to other parts of the body and to start the growth of a new tumor there.

This research might also open new methods of treatment for disorders that are accompanied by a shortage of oxygen, such as myocardial infarction or stroke. The researchers also hope to be able to use this discovery to tackle the morbid growth of blood vessels in the retina. Questions Given that this research can raise a lot of questions, we ask you to please refer questions in your report or article to the e-mail address that VIB makes available for this purpose: patienteninfo@vib.be. Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.

Funding

This research has been funded by: EMBO, Deutsche Krebshilfe, DFG, FEBS, Methusalem Grant, the European Union, Concerted Research Activities, Belgian Science Policy, Programme Grant, British Heart Foundation, FWO, K.U.Leuven and VIB.